Search 

Neurodyn Inc. (neurodyn.ca) is a Canadian biotechnology company using a portfolio approach to identifying, validating and developing natural bioactives into both prescription drugs and natural products for the early treatment of Alzheimer's Disease, Parkinson's Disease and other neurodegernative disorders. 

Memogain® is a patented pro-drug of an existing major Alzheimer's cognition enhancement drug, offering improved side effect profile and increased bioavailability. Initial Phase 1A results have been positive, showing no significant side effects and improved working memory in young and elderly volunteers. Memogain may qualify for a new US FDA accelterated pathway or Eu equivalent.

Cerbella™ is a treatment for early stage Parkinson's disease which has demonstrated in-vivo pre-clinical efficacy in acute models as well as Neurodyn's proprietary chronic model of Parkinson's disease. A product is expected to launch in Canada, USA or other countries in 2015.

NeuroPro® is a professionally-oriented supplement launched in October 2013, designed for neuroprotection and bansed on 5 years of animal model research.

Nerve Pain Treatment (PN34) is a rare first-in-class neuromodulator, being prepared for a topical orphan status nerve paincondition, with clinical trials to begin in 2015.

Progranulin (ND602) is a novel therapeutic demonstrating in-vivo pre-clinical efficacy in ALS, PD< Alzheimer's disease and Spinal Muscular Atrophy. The company is in its third year of collaboration (late stage pre-clinical evaluation) with the Michael J. Fox Foundation.

Neuro Networks Fund is a Venture Philanthropy fund that was established in 213. The fund is looking to make equity investments into companies and projects ranging from $25 for research projects and up to $5 million for early stage companies. The firm will reinvest all returns from these investments back into its fund in an evergreen structure. The firm hopes to begin making its first investments as soon as Q4 214 but is currently very open to discussion and networking with companies in its target sectors. The firm is open to review opportunities from around the globe.

NeuroTronik Limited is a development-stage, venture-backed medical device company pursuing a unique neuromodulation approach to improve cardac output for patients who come to the hospital with Acute Heart Failure Syndrome. With a seasoned team of engineers, advisors, and investors, NeuroTronik is on-track in project milestone achievement. Though a moderately-sized project, the market potential is exceptional.

NeuroTronik is planning a $20 million Series B preferred stock financing in late 2015. Those proceeds are designed to take the therapy through and into commercial sales in Europe.

Our named investors are Hatteras Venture Partners, Synergy Life Science Partners, Mountain Group Capital, and Lord Baltimore Capital.

The CEO is Fred McCoy. The CTO is Steve Masson.

New Leaf Venture Partners is a venture capital company formed in 25 with offices in New York and San Mateo California. The firm currently manages two funds with its most recent fund having closed at $45 million in 27. The firm is looking to make equity investments ranging from $1-$25 million over the lifetime of the investment. The firm looks for companies primarily in the United States and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

Norfolk Medical pioneered the oncology market in 1981 by developing one of the first vascular access ports for long-term access.  Since then, we have continued to develop innovative cutting-edge medical devices.  Our latest development is a device for diabetes that allows the body to be insulin independent.  Our device is the world's first active immunoisolation device that facilitates the exchange of oxygen, nutrients, and waste products while protecting against the bodies immune response without the use of additional drugs or immunosuppressant’s.  We are confident that the basic principles of the device can be applied to other applications from anemia and liver failure (NASH) to ALS.  We are currently in the pre-clinical stage of research and are actively looking for a strategic partner to develop this product.